CatalystMarker
← board

ZVSA

ZyVersa Therapeutics, Inc.distress 5/10 · elevated risk
$0.12+2%today-80% from 52w high
zyversa.com6 employeesFounded 2014Weston, FLBiotechnology
Metabolic / Obesity 1
Lead: Diabetic Kidney Disease
Revenue
pre-revenue
Liquidity
$0M
Runway
0.1 yrs
Shares 1y
0%

Price & events

-34.4% over 6M
$0.11$0.19$0.27Jan 26Apr 26Jul 26212kfinancing: 8-K material_agreement (2026-03-05)
CatalystRating changeDilutionFinancingdashed = today
+1.7%
1D
-7.1%
1W
-28.5%
1M
-43.8%
3M
-34.4%
6M
-20.3%
1Y
-96.9%
2Y
—
5Y
-100.0%
All

Overview

Market Cap
$955.32K
Volume
2.80K
52 Week Range
$0.11 – $0.59
Total Shares
8.10M
Float Shares
7.68M
Short %
7.38%
% Held by Insiders
0.02%
% Held by Institutions
5.15%
RVOL
0.16x
Beta
0.83

Pipeline stages · 1 programs

2HPβCD
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
next 2026-08-11

Pipeline · 1 trials · 1 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2026-08-11
Estimated 50%
readout ~2026-09-25
Phase 22HPβCDDiabetic Kidney Disease0withdrawn

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 8,095,921 · 0 offerings/1y · 0 PIPEs
  • 2026-03-058-Kmaterial_agreement
  • 2025-08-06EFFECTshelf_effective
  • 2025-08-01S-1/Ashelf_registration
  • 2025-07-18S-1/Ashelf_registration
  • 2025-07-098-Kprivate_placement
  • 2025-07-02S-1shelf_registration
  • 2025-06-258-Kprivate_placement
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • no recent rating changes

Competitors — Diabetic Kidney Disease

  • REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.